X0206 3 2023-01-01 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001957554 Balthaser Kevin C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 0 1 0 0 Chief Financial Officer Common Stock 700 D Employee Stock Option (Right to Buy) 27.54 2027-07-04 Common Stock 11200 D Employee Stock Option (Right to Buy) 22.09 2028-01-31 Common Stock 2100 D Employee Stock Option (Right to Buy) 24.06 2031-02-28 Common Stock 15500 D Employee Stock Option (Right to Buy) 14.94 2032-02-29 Common Stock 33400 D Restricted Stock Units Common Stock 1475 D Restricted Stock Units Common Stock 3000 D Restricted Stock Units Common Stock 2000 D Restricted Stock Units Common Stock 3300 D Restricted Stock Units Common Stock 9500 D The shares underlying this option are fully vested. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option. The option vests over a period of four years. 25% of the shares are currently vested with the remaining 75% vesting annually on March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option. The option vests over a period of four years. 25% of the shares will vest on March 1, 2023, with the remaining 75% vesting annually thereafter on March 1, 2024, March 1, 2025 and March 1, 2026, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The expiration date of this option reported in the table is the day before the tenth anniversary of the grant date of the option. The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. Exhibit 24.1 - Power of Attorney /s/ Mark Ballantyne, as Attorney-in-Fact 2023-01-06